Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;8(12):778.
doi: 10.21037/atm.2020.02.68.

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

Fiona Mienko  1 , Balazs Halmos  1 , Haiying Cheng  1
Affiliations
Editorial

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

Fiona Mienko et al. Ann Transl Med. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.02.68). BH has received research funding from Merck, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Novartis, GSK, AbbVie, Mirati, Eli-Lilly, Takeda and BMS and consulting fees from Foundation Medicine, Guardant Health 360, Eli-Lilly, Novartis, Pfizer, BoehringerIngelheim, Astra-Zeneca, Spectrum, BMS, Merck, Genentech and Takeda. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Maione P, Rossi A, Sacco PC, et al. Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol 2010;2:251-60. 10.1177/1758834010366707 - DOI - PMC - PubMed
    1. Bravo-Iñiguez C, Perez Martinez M, Armstrong KW, et al. Surgical resection of lung cancer in the elderly. Thorac Surg Clin 2014;24:371-81. 10.1016/j.thorsurg.2014.07.001 - DOI - PubMed
    1. O'Connor JM, Fessele KL, Steiner J, et al. Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials. JAMA Oncol 2018;4:e180798. 10.1001/jamaoncol.2018.0798 - DOI - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed